ABSTRACT
Children are less susceptible to SARS-CoV-2 and typically have milder illness courses than adults. We studied the nasopharyngeal microbiomes of 274 children, adolescents, and young adults with SARS-CoV-2 exposure using 16S rRNA gene sequencing. We find that higher abundances of Corynebacterium species are associated with SARS-CoV-2 infection and SARS-CoV-2-associated respiratory symptoms, while higher abundances of Dolosigranulum pigrum are present in SARS-CoV-2-infected individuals without respiratory symptoms. We also demonstrate that the abundances of these bacteria are strongly, and independently, associated with age, suggesting that the nasopharyngeal microbiome may be a potentially modifiable mechanism by which age influences SARS-CoV-2 susceptibility and severity.
Summary Evaluation of nasopharyngeal microbiome profiles in children, adolescents, and young adults with a SARS-CoV-2-infected close contact identified specific bacterial species that vary in abundance with age and are associated with SARS-CoV-2 susceptibility and the presence of SARS-CoV-2-associated respiratory symptoms.
Competing Interest Statement
MSK reports advisory board feeds from Adagio Therapeutics, Inc. CWW reports advisory board fees from Roche Molecular Sciences, non-financial support from bioMerieux and Becton Dickinson, a research collaboration with Biofire, and is co-founder of Predigen. All other authors have no competing interests to declare.
Funding Statement
This work was funded by the Duke University School of Medicine and through grants from the Duke Microbiome Center, Childrens Miracle Network Hospitals, and the Translating Duke Health Childrens Health and Discovery Initiative. AWM was supported by a grant from the National Science Foundation (DGE-1545220). SMH was supported by National Institutes of Health (NIH) training grant (T32-HD094671). MSK was supported by a NIH Career Development Award (K23-AI135090).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Duke University Health System Institutional Review Board. Written informed consent was obtained from all participants or their legal guardian.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The sequencing dataset supporting the conclusions of this study is available in the Sequence Read Archive (PRJNA703574). The statistical files and script used for data analyses are also publicly available (https://github.com/alexmccumber/BRAVE_Kids).